How many insider trades does FilingIQ track for DRUG?

FilingIQ tracks 13 Form 4 insider transactions for DRUG (BRIGHT MINDS BIOSCIENCES INC.), covering filings from Oct 15, 2024 onwards. 1 of those were filed in the last 90 days.

Are DRUG insiders net buyers or net sellers?

Across the full Form 4 history for DRUG, 12 transactions (92%) were open-market purchases and 1 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DRUG insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DRUG in?

BRIGHT MINDS BIOSCIENCES INC. (DRUG) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $759.88M.

DRUG insider trading

NasdaqCM Healthcare

BRIGHT MINDS BIOSCIENCES INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

92% / 8%

Market cap

$759.88M

About BRIGHT MINDS BIOSCIENCES INC.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Company website: brightmindsbio.com

DRUG insider activity at a glance

FilingIQ has scored 13 insider transactions for DRUG since Oct 15, 2024. The most recent filing in our index is dated Apr 28, 2026.

Across the full history, 12 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DRUG insider trades is 46.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DRUG trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for DRUG?: FilingIQ tracks 13 Form 4 insider transactions for DRUG (BRIGHT MINDS BIOSCIENCES INC.), covering filings from Oct 15, 2024 onwards. 1 of those were filed in the last 90 days.
Are DRUG insiders net buyers or net sellers?: Across the full Form 4 history for DRUG, 12 transactions (92%) were open-market purchases and 1 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DRUG insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DRUG in?: BRIGHT MINDS BIOSCIENCES INC. (DRUG) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $759.88M.

Methodology & sources

Every DRUG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.